aTYR PHARMA (ATYR) Gains from Investment Securities (2014 - 2015)
aTYR PHARMA's (ATYR) quarterly Gains from Investment Securities came in at $48000.0 in Q2 2015, down 12.73% on a YoY basis from $55000.0 in Q2 2014, and up 162.34% quarter-over-quarter from -$77000.0 in Q1 2015.
Powered by 
Analysis
aTYR PHARMA (ATYR) Gains from Investment Securities (2014 - 2015) Analysis & Trends
aTYR PHARMA (ATYR) has reported Gains from Investment Securities for 2 consecutive years, with $48000.0 the latest figure, recorded in Q2 2015.
- For the quarter ending Q2 2015, Gains from Investment Securities fell 12.73% year-over-year to $48000.0; the trailing twelve-month figure through Dec 2015 stood at -$29000.0 (up 19.44% YoY), and the FY2015 full-year result was -$29000.0, up 19.44% from the prior year.
- Gains from Investment Securities climbed to $48000.0 in Q2 2015 per ATYR's latest filing, from -$77000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $128000.0 in Q3 2014 and bottomed at -$249000.0 in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2015 | 48,000.00 |
| Mar 31, 2015 | -77,000.00 |
| Dec 31, 2014 | -249,000.00 |
| Sep 30, 2014 | 128,000.00 |
| Jun 30, 2014 | 55,000.00 |
| Mar 31, 2014 | 30,000.00 |